Can I Take Ashwagandha With AndroGel?

What Is the Interaction Between Ashwagandha and AndroGel?

The interaction is pharmacodynamic, not pharmacokinetic. AndroGel delivers exogenous testosterone transdermally. Ashwagandha (Withania somnifera) raises endogenous testosterone through a separate pathway involving the hypothalamic-pituitary-gonadal (HPG) axis and cortisol suppression. Neither agent meaningfully alters the other's absorption, protein binding, or hepatic clearance. The concern is that both push testosterone in the same direction at the same time.

How AndroGel Works

AndroGel delivers testosterone through the skin at a controlled rate. The 1% formulation (50-100 mg applied daily) and the 1.62% formulation (20.25-81 mg daily) are both approved by the FDA for male hypogonadism [1]. Once absorbed, testosterone suppresses LH and FSH via negative feedback, effectively halting testicular production. The gel alone determines circulating androgen levels in most men on stable therapy.

How Ashwagandha Raises Testosterone

Ashwagandha does not contain testosterone. Instead, it acts on the HPG axis and adrenal cortex. The proposed mechanisms include reducing cortisol (which at chronically high levels suppresses gonadotropin-releasing hormone), modulating DHEA-S production, and possibly acting as a steroidal lactone precursor via withanolides [2]. In men on AndroGel, the HPG axis is already suppressed by exogenous hormone, so the LH/FSH route is largely blocked. The cortisol-reduction and adrenal effects may still operate independently, potentially adding to circulating androgen load through DHEA-S conversion pathways.

Why This Distinction Matters Clinically

Because the mechanisms are independent, standard drug-interaction databases (which flag pharmacokinetic collisions) often return "no known interaction" for this pair. That answer is technically correct but clinically incomplete. The real question is whether two androgen-raising interventions in the same patient can combine to push total testosterone above the therapeutic window (generally 400-700 ng/dL for replacement therapy per Endocrine Society guidelines) [3].

What Does the Clinical Evidence Say About Ashwagandha and Testosterone?

Several randomized controlled trials have measured ashwagandha's effect on testosterone in men, and the effect sizes are real, if modest.

The Wankhede 2015 Trial (KSM-66, N=57)

A double-blind RCT published in the Journal of the International Society of Sports Nutrition enrolled 57 male resistance-trained subjects aged 18-50. Participants received either KSM-66 ashwagandha 300 mg twice daily or placebo for 8 weeks. Serum testosterone rose by 96.2 ng/dL (+15.4%) in the ashwagandha group versus 18.0 ng/dL (+2.6%) in placebo (P<0.001) [4]. Cortisol fell by 27.9% in the treatment arm. This is one of the most-cited trials in this space and establishes a measurable androgenic signal.

The Ambiye 2013 Trial (Sensoril, N=46)

An earlier placebo-controlled trial using Sensoril ashwagandha 225 mg twice daily in 46 infertile men showed a 17% increase in serum testosterone and a 36% increase in luteinizing hormone after 90 days [5]. This trial enrolled men with oligospermia, a population with compromised HPG function, yet still demonstrated significant gonadotropin and testosterone responses. The luteinizing hormone finding confirms HPG-axis engagement as one mechanism.

The Lopresti 2019 Trial (N=60)

A randomized, double-blind, placebo-controlled study in 60 men aged 40-70 with self-reported fatigue tested KSM-66 at 240 mg daily for 8 weeks [6]. DHEA-S rose by 18.0% and testosterone by 14.7% in the treatment group. The DHEA-S increase is particularly relevant when combined with AndroGel because adrenal androgens can be peripherally converted to testosterone, adding to the exogenous load from the gel.

What Are the Risks of Combining Both?

Supraphysiologic Testosterone

AndroGel is already titrated to reach a target total testosterone range. Adding 15-17% on top of a dialed-in regimen may push levels into the supraphysiologic range (above 1,050 ng/dL per FDA labeling thresholds) [1]. Sustained supraphysiologic levels are associated with increased erythrocytosis, dyslipidemia, and cardiovascular risk [7].

Erythrocytosis

Testosterone stimulates erythropoietin, raising red blood cell mass and hematocrit. The FDA-approved labeling for AndroGel specifies that therapy should be stopped or dose-reduced if hematocrit exceeds 54% [1]. A systematic review published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy raises hematocrit in a dose-dependent fashion, and the effect is amplified when baseline testosterone is already normal-to-high [7]. Adding ashwagandha's androgen contribution to an existing TRT regimen increases this risk in a cumulative way.

Thyroid-Axis Considerations

Ashwagandha has documented thyroid-stimulating effects. A randomized controlled trial published in Medicine (Baltimore) in 2018 enrolled 50 adults with subclinical hypothyroidism and found that 600 mg/day of ashwagandha root extract for 8 weeks significantly raised T3 and T4 and lowered TSH compared with placebo (P<0.05) [8]. Testosterone therapy itself can lower SHBG and alter thyroid hormone binding. Combining both agents creates the possibility of thyroid-axis changes that standard AndroGel monitoring panels do not routinely capture, because prescribers rarely check TSH when managing TRT.

Cortisol Suppression

Ashwagandha consistently lowers salivary and serum cortisol in clinical trials. A 2019 RCT in Medicine (Baltimore) (N=58) found 240 mg daily of ashwagandha reduced cortisol by 23% over 60 days (P<0.05) [9]. While lower cortisol is often desirable, men on testosterone replacement who also train intensely may find that blunted cortisol signaling after hard exercise impairs appropriate immune and metabolic stress responses. This is a low-probability concern but one worth noting in clinical context.

Is Dose Separation Necessary?

No pharmacokinetic reason exists to separate the timing of AndroGel application and ashwagandha ingestion. AndroGel is absorbed transdermally over 6-8 hours and reaches steady-state within about 24-48 hours after the first application [1]. Ashwagandha is taken orally and metabolized hepatically. The two agents do not share absorption sites, transporters (CYP enzymes are not meaningfully involved in testosterone gel pharmacokinetics at clinical doses), or protein-binding competition [2].

The practical separation guidance, if any, is clinical rather than pharmacokinetic: establish a stable total-testosterone level on AndroGel alone for at least 6-8 weeks, obtain labs, then add ashwagandha with repeat labs 8 weeks later. This gives a clean before-and-after comparison.

Who Should Be Most Cautious?

Certain patients carry higher risk when adding ashwagandha to an existing AndroGel prescription. The clinical risk stratification below is organized by monitoring priority.

High Monitoring Priority

• Men with hematocrit already above 48% at baseline
• Men with a history of polycythemia vera or sleep apnea (both worsen with androgen excess)
• Men with known or subclinical hypothyroidism or hyperthyroidism
• Men taking concurrent thyroid medication (levothyroxine, liothyronine)
• Men with prostate cancer history or elevated PSA (above 3.0 ng/mL)

Moderate Monitoring Priority

• Men with cardiovascular disease or a 10-year ASCVD risk above 10%
• Men whose AndroGel dose was titrated upward within the last 3 months
• Men using compounded testosterone products where batch-to-batch potency may vary

Lower Monitoring Priority (but still worth disclosure)

• Otherwise-healthy men with confirmed hypogonadism (total T below 300 ng/dL before treatment), stable on AndroGel for over 12 months, with a hematocrit consistently below 46%, no thyroid history, and PSA below 2.0 ng/mL

Even the lower-priority group should disclose ashwagandha use to their prescriber. The supplement is not on the standard medication reconciliation list at most pharmacies, so the default is under-reporting.

What Lab Monitoring Is Recommended?

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends monitoring total testosterone, hematocrit, PSA, and bone density at defined intervals during TRT [3]. The guideline does not address supplement co-administration specifically, but its monitoring framework can be adapted.

Recommended Labs Before Adding Ashwagandha

• Total testosterone and free testosterone (morning draw, before gel application)
• Hematocrit and hemoglobin
• PSA
• TSH and free T3 (given ashwagandha's thyroid signal)
• LH and FSH (to document suppression status on current AndroGel dose)
• Comprehensive metabolic panel

Recommended Labs 8 Weeks After Starting Ashwagandha

• Repeat total and free testosterone
• Repeat hematocrit
• Repeat TSH and free T3
• Symptom review: sleep quality, libido, mood, energy, urinary symptoms

If total testosterone rises above 1,050 ng/dL or hematocrit exceeds 52%, the clinician should consider reducing the AndroGel dose rather than simply stopping ashwagandha. Stopping the supplement abruptly while continuing the gel may leave the patient in a normal or sub-therapeutic range depending on how much of the testosterone signal was driven by the root extract.

Can Ashwagandha Replace or Reduce the Need for AndroGel?

Ashwagandha is not an approved therapy for male hypogonadism. The FDA has not evaluated it for this indication, and no trial has compared it directly to prescription testosterone therapy in men with confirmed hypogonadism (total T below 300 ng/dL on two morning measurements) [1][3].

In the trials cited above, most subjects had low-normal or normal baseline testosterone. A 15-17% increase from a normal baseline is not the same as the 200-400 ng/dL absolute rise often needed to take a hypogonadal man from below 300 to within the therapeutic range. Ashwagandha should be considered a complementary agent with a modest androgenic signal, not a substitute for a prescribed hormone.

Some men on AndroGel who achieve consistent mid-range testosterone levels (450-650 ng/dL) and want to try reducing their gel dose may ask whether ashwagandha could help maintain levels. This is a reasonable clinical conversation to have with the prescribing physician, supported by a planned dose-reduction protocol and scheduled follow-up labs 8 weeks post-reduction. Do not attempt self-guided dose reduction.

What About Ashwagandha and Transdermal Transfer Risk?

AndroGel carries a black-box warning for secondary exposure risk: transfer of testosterone to women and children through skin contact [1]. Ashwagandha does not affect transdermal transfer rates of testosterone gel. These are completely separate safety considerations. Men using AndroGel should follow all standard transfer-prevention guidance (covering the application site, washing hands, avoiding skin-to-skin contact until the gel dries) regardless of whether they are also taking ashwagandha.

What Should You Do If You Are Already Taking Both?

If you started ashwagandha without discussing it with your AndroGel prescriber, do not abruptly stop either agent. The appropriate steps are:

1. Schedule a lab draw (total T, free T, hematocrit, TSH, free T3) as soon as possible.
2. Bring the ashwagandha product to your appointment, including lot number and standardized extract percentage.
3. Let your clinician review current levels against your last recorded AndroGel-only baseline.
4. Agree on a monitoring schedule before deciding whether to continue, adjust, or discontinue the supplement.

Abrupt cessation of ashwagandha is not dangerous, but abrupt AndroGel cessation can produce withdrawal symptoms (fatigue, mood changes, reduced libido) within days and should never be self-directed.

Key Takeaways by the Numbers

To summarize the most clinically relevant figures from the primary literature:

• AndroGel 1.62% at 81 mg/day raises mean steady-state testosterone to approximately 560 ng/dL in clinical trials [1].
• Ashwagandha KSM-66 at 300 mg twice daily raised testosterone by a mean of 96.2 ng/dL in 8 weeks in the Wankhede 2015 RCT (P<0.001) [4].
• Ashwagandha raised DHEA-S by 18% in the Lopresti 2019 trial, a relevant adrenal androgen precursor [6].
• TSH fell and T3/T4 rose significantly with ashwagandha 600 mg/day in 8 weeks in a published RCT of 50 adults (P<0.05) [8].
• Hematocrit monitoring thresholds per FDA labeling: withhold AndroGel if hematocrit exceeds 54% [1].
• Endocrine Society guideline target range for testosterone replacement therapy: 400-700 ng/dL (mid-normal range for healthy young men) [3].

A man already reaching 560 ng/dL on AndroGel who adds ashwagandha and experiences a 96 ng/dL increase would reach approximately 656 ng/dL, still within range. But individual variation is wide. Men at the higher end of their current range could exceed 1,050 ng/dL, triggering the FDA labeling threshold for dose reduction.

Schedule labs before starting ashwagandha. Recheck at 8 weeks. Keep total testosterone within 400-700 ng/dL and hematocrit below 52%.